Published in Clin J Am Soc Nephrol on September 08, 2015
Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study. J Clin Endocrinol Metab (2016) 0.82
Phosphate Toxicity in CKD: The Killer among Us. Clin J Am Soc Nephrol (2016) 0.77
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol (2016) 0.76
Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice. Bone (2016) 0.76
Nutrition in Cardioskeletal Health. Adv Nutr (2016) 0.75
Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting? J Nephrol (2017) 0.75
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 16.18
Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 13.77
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 7.41
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol (2003) 6.99
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int (2006) 6.61
Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol (2004) 6.59
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 5.29
Phosphate regulation of vascular smooth muscle cell calcification. Circ Res (2000) 5.18
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59
Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant (2000) 3.99
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab (2001) 3.55
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab (2006) 3.08
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab (2004) 2.83
Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem (2004) 2.72
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int (2011) 2.71
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol (2010) 2.67
Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int (1989) 2.55
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest (1990) 2.25
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22
Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol (2010) 2.20
PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol (2010) 2.19
Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol (2008) 2.18
Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol (2004) 2.17
Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev (2000) 2.17
Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int (2006) 2.10
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis (2004) 1.93
Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol (2007) 1.92
Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res (2002) 1.84
Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol Dial Transplant (2007) 1.83
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol (2009) 1.78
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66
Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60
Latest findings in phosphate homeostasis. Kidney Int (2009) 1.57
Low socioeconomic status associates with higher serum phosphate irrespective of race. J Am Soc Nephrol (2010) 1.46
Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest (1984) 1.44
Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol (2012) 1.42
Control of phosphate excretion in uremic man. J Clin Invest (1968) 1.41
The control of phosphate excretion in uremia. J Clin Invest (1966) 1.36
On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int (1972) 1.34
Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules. Am J Physiol (1995) 1.30
Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol (2014) 1.16
The expanding family of hypophosphatemic syndromes. J Bone Miner Metab (2011) 1.14
Trophic effect of human pericardial fluid on adult cardiac myocytes. Differential role of fibroblast growth factor-2 and factors related to ventricular hypertrophy. Circ Res (1997) 1.12
Calcium regulates FGF-23 expression in bone. Endocrinology (2013) 1.09
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol (2014) 1.06
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol (2014) 1.06
Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats. Exp Physiol (1998) 1.01
Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis (2013) 0.98
Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens (2012) 0.98
Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant (2014) 0.91
Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol (2013) 0.90
Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis (2014) 0.90
Sodium- and phosphorus-based food additives: persistent but surmountable hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis (2013) 0.90
The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol (2014) 0.86
Human parathyroid hormone inhibits renal 24-hydroxylase activity of 25-hydroxyvitamin D3 by a mechanism involving adenosine 3',5'-monophosphate in rats. Endocrinology (1986) 0.76
In search of the fountain of youth. J Am Soc Nephrol (2014) 0.79